Concepedia

Author

Kai Yuan

China Pharmaceutical UniversityORCID

Also Known As

Kai Yuan

44

Publications

771

Citations

14

H-Index

11

Concepts

All Affiliations

China Pharmaceutical UniversityState Key Laboratory of Natural MedicineChinese Academy of Medical Sciences & Peking Union Medical CollegeSouthern Medical UniversityNanfang Hospital
KY

About

Kai Yuan is an author at China Pharmaceutical University specializing in engineering, organic chemistry, and drug discovery.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Engineering

1

1

69

2

Medicine

1

1

17

3

Biomolecular Engineering

1

1

69

4

Chemistry

1

1

69

5

Pharmacology

1

1

17

Kai Yuan

×

16

Publications

432

Citations

13

H-Index

YearCitations

Rh(III)-Catalyzed Cascade Annulation/C–H Activation of <i>o</i>-Ethynylanilines with Diazo Compounds: One-Pot Synthesis of Benzo[<i>a</i>]carbazoles via 1,4-Rhodium Migration

Songjin Guo, Kai Yuan, Meng Gu,

Organic Letters

2016

69

Antiproliferation and cell apoptosis inducing bioactivities of constituents from Dysosma versipellis in PC3 and Bcap-37 cell lines

Xiaoqiang Xu, Xiu-Hong Gao, Linhong Jin,

Cell Division

2011

56

Palladium-Catalyzed Cascade Heck Cyclization To Access Bisindoles

Kai Yuan, Lina Liu, Jiayi Chen,

Organic Letters

2018

51

Advanced Oxidation Protein Products Induce Inflammatory Response in Fibroblast-Like Synoviocytes through NADPH Oxidase -Dependent Activation of NF-κB

Shuai Zheng, Zhaoming Zhong, Shuai Qin,

Cellular Physiology and Biochemistry

2013

43

Novel Small-Molecule PD-L1 Inhibitor Induces PD-L1 Internalization and Optimizes the Immune Microenvironment

Chengliang Sun, Mingxiao Yin, Yao Cheng,

Journal of Medicinal Chemistry

2022

39

Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents

Chengliang Sun, Yao Cheng, Xiaojia Liu,

Acta Pharmaceutica Sinica B

2022

31

Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancer

Kai Yuan, Zhaoxing Li, Wenbin Kuang,

Nature Communications

2022

18

Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma

Kai Yuan, Wenbin Kuang, Weijiao Chen,

European Journal of Medicinal Chemistry

2021

17

Discovery of Novel and Selective CDK4/6 Inhibitors By Pharmacophore and structure-based Virtual Screening

Kai Yuan, Wenjian Min, Xiao Wang,

Future Medicinal Chemistry

2020

16

Design, Synthesis, and Antitumor Activity Evaluation of Novel VISTA Small Molecule Inhibitors

Chengliang Sun, Yuling He, Gefei Wang,

Journal of Medicinal Chemistry

2024

16

Page 1